You Can Survive Aggressive Prostate Cancer With Hormone Therapy And Radiation – New Study Says

November 8, 2011 by  
Filed under Prostate Cancer News

Do You Want To Make Money Online?

You Will Be Blown Away

Like we always say in this Prostate Cancer Website, more and more studies are being done on an almost daily basis to provide more solutions and better research for surviving prostate cancer. We owe the many researchers a lot for the awesome findings they come up with; many helping to save lots of lives from the scourge of this cancer.

One of such researches/studies has just indicated that those men who have had their cancers spread out of their prostate to other surrounding tissues (thus have aggressive prostate cancer) can now live much longer than previously thought, if they are treated using a combination of hormone therapy and radiation.

Read more about this in the below news article:

Men with prostate cancer that has spread to local surrounding tissues live longer and are less likely to die of the high-risk disease if treated with a combination of radiation and hormone therapy, rather than with the drug treatment alone, a study has found.

The finding could change the standard for treating this aggressive form of prostate cancer, which represents about one in five cases of the disease, said Dr. Padraig Warde, a radiation oncologist at Princess Margaret Hospital in Toronto who led the international study.

“The study shows combining radiation and hormone therapy improves overall survival by 23 per cent and disease-specific survival by 43 per cent, compared with treating with hormone therapy alone,” said Warde.

To conduct the study, 1,205 men with locally advanced prostate cancer in Canada, the U.S. and the U.K. were randomly divided into two groups. Half received androgen-deprivation therapy to suppress testosterone production, while the other half were treated with the hormone therapy plus radiation.

After seven years, 66 per cent of men who had the hormone therapy alone were still alive, compared with 74 per cent who received the combination treatment. Among those in the hormone treatment-only group, 26 per cent died from their prostate cancer, compared with 10 per cent who received both therapies.

“The two of them together combined are the important thing,” said Warde. “You can’t use radiation alone. What it’s showing is that radiation plus hormones are better than hormones alone.”

Androgen deprivation therapy, given by intramuscular injection, works by starving prostate cancer cells of testosterone, which they need to multiply. The treatment also makes cancer cells more sensitive to the killing effects of radiation, Warde explained.

This year, an estimated 25,500 men in Canada will be diagnosed with cancer of the walnut-sided gland, and about 4,100 will die of the disease. About 15 to 20 per cent of cases are the aggressive or high-risk type with localized spread.

“And these are the bad actors,” said Warde of this form of the cancer. “These are the patients, if you look overall, who die of prostate cancer, whereas many of the people who present with earlier-stage disease, they actually will live very long even with or without treatment. They don’t die of prostate cancer — they die with it.

“But with these ones, a lot of the patients will die of prostate cancer.”

The study is published in the Nov. 2 issue of The Lancet, and Warde believes its findings will alter the practice of using just hormone therapy for locally advanced prostate cancer.

“There is substantial evidence that many, many patients … are treated with hormone therapy alone and are never referred for consideration of (radiation) treatment,” he said. “So they’re never given the chance of cure because with locally advanced disease, many urologists in particular — although I’m not picking on them — believed that this is incurable cancer and there was really no point in giving them additional treatment beyond hormones.”

The international research team enrolled and treated patients over 10 years beginning in 1995, and Warde said the radiation therapy used was typically “old-style” — employing lower doses of radiation in less finely targeted beams, compared with treatment today.

“So, in fact, there’s every reason to believe that with the radiation we use now … that the results are likely to be much better because we hopefully kill more cancer cells with the radiation and we’re much more precise now,” he said.

Some side-effects can occur, however, including damage to surrounding tissues like the rectum and bladder, which can cause tenderness, some bleeding and diarrhea. Warde said these effects are most pronounced in the first six to 12 months on average, but don’t seem to persist beyond three years following treatment.

Still, he believes that adding the radiation component will lead to a better outcome for many patients.

“It’s practice-changing in that we will be getting out to patients, physicians across North America and Europe … that actually these patients should no longer be treated with hormone therapy alone. They should be referred for consideration of radiation, and hopefully many of them will benefit and live longer and more productive lives.”

Dr. Martin Gleave, director of the Vancouver Prostate Centre, does not see the study so much as a “game-changer,” but a confirmation of what cancer specialists have surmised for some time.

“The fact that adding radiation helps survival affirms our biases,” Gleave, a professor of urology at the University of British Columbia, said from Vancouver. “But on top of that, I think it will lead us in the future towards being more aggressive in managing the local disease.”

“Where we would have thought, or at least hypothesized, that maybe the horse is out of the barn and closing the barn door doesn’t make a difference … (the study suggests that) closing the barn door and preventing more horses from getting out does make a difference,” he said of the double-barrelled treatment to halt the migration of cancer cells.

Gleave said more aggressive treatment could mean using chemotherapy along with hormone-suppression and radiation, a triple combination that Warde’s team has already begun testing. Surgery might also be included in such a treatment regimen, Gleave added. Read more.

As you can see from the above news article, it’s never too late to give up, even if you have aggressive or end stage prostate cancer.

There’s always hope, like we like to say on this website… so you should always be POSITIVE while looking for how to survive prostate cancer!

Click Here To Find More Tips For Free Yes, It's Completely Free Tips

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. Early Hormone Therapy Radiation Prostate Cancer
  2. Early Hormone Therapy Radiation for Men with Prostate Cancer
  3. Prostate Cancer Treatment Hormone Therapy
  4. Prostate Hormone Therapy Treatment
  5. Prostate Cancer Hormonal Treatment and Radiation Therapy
  6. Hormone Therapy 26 Prostate Cancer
  7. Prostate Cancer Hormone Therapy Treatment
  8. Hormone Therapy for Prostrate Cancer – How Effective Is It?
  9. Why Hormone Therapy For Prostate Cancer And Survival Rates
  10. Millions Of People Don’T Know About Prostate Cancer Hormone Therapy
  11. Side Effects Of Prostate Cancer Androgen Hormone Therapy
  12. Prostate Cancer Androgen Hormone Therapy Side Effects
  13. Intensity Modulated Radiation Therapy for Prostrate Cancer (IMRT)
  14. IMRT or Intensity Modulated Radiation Therapy Treatment for Prostate Cancer
  15. Prostate Brachytherapy And IMRT -Intensity Modulated Radiation Therapy

Speak Your Mind

Tell us what you're thinking... !